MedTrace Logo

Combined Use of Bacteroides Fragilis and BCAAs on HBsAg Clearance

NCT07257562 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2025-12-02

No results posted yet for this study

Summary

The goal of this prospective observational study is to determine the effects of concomitant administration of Bacteroides fragilis and Branched-Chain Amino Acids on hepatitis B virus clearance. The primary question it aims to answer is whether this concomitant administration can promote HBV clearance.

The study will observe the HBV clearance rate in chronic hepatitis B patients who receive Bacteroides fragilis and BCAA as a supplement to their routine antiviral therapy. For comparison, researchers will compare the clearance rate in this group to that observed in a control group of chronic hepatitis B patients receiving a standard antiviral regimen based on PegIFNα2b and nucleoside analogs.

Conditions

Interventions

DRUG

PegIFNα2b+Nucleoside analog

The patients receive both PegIFNα2b and Nucleoside analog therapy.

DRUG

PegIFNα2b+Nucleoside analog+Bacteroides fragilis+Branched-Chain Amino Acids

The patients received the concomitant administration of Bacteroides fragilis and BCAA, supplemented to their ongoing combination therapy with PegIFNα2b and Nucleoside analog.

Sponsors & Collaborators

  • First Affiliated Hospital of Fujian Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2026-03-01
Completion
2026-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07257562 on ClinicalTrials.gov